Русская версия English version   
О журнале
Редакционная коллегия
Правила для авторов
Информация для читателей и авторов
Оглавление текущего номера
Архив
Контакты
Поиск

Отправить статью
 


Том 20   Выпуск 1   Год 2025
Список литературы

  1. Feigin V.L., Vos T., Nichols E., Owolabi M.O., Carroll W.M., Dichgans M., Deuschl G., Parmar P., Brainin M., Murray C. The Global Burden of Neurological Disorders: Translating Evidence into Policy. Lancet Neurol. 2020;19:255–265. doi: 10.1016/S1474-4422(19)30411-9
  2. Steinmetz J.D., Seeher K.M., Schiess N., Nichols E., Cao B., Servili C., Cavallera V., Cousin E., Hagins H., Moberg M.E., et al. Global, Regional, and National Burden of Disorders Affecting the Nervous System, 1990–2021: A Systematic Analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024. V.23:344–381. doi: 10.1016/S1474-4422(24)00038-3
  3. Vallés A.S., Barrantes F.J. Nicotinic Acetylcholine Receptor Dysfunction in Addiction and in Some Neurodegenerative and Neuropsychiatric Diseases. Cells. 2023;12(16). doi: 10.3390/cells12162051
  4. Blennow K., de Leon M.J., Zetterberg H. Alzheimer’s disease. The Lancet. 2006;368:387-403. doi: 10.1016/S0140-6736(06)69113-7
  5. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. USA. 1985;82:4245–4249. doi: 10.1073/pnas.82.12.4245
  6. Cras P., Kawai M., Lowery D., Gonzalez-DeWhitt P., Greenberg B., Perry G. Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein. Proc. Natl. Acad. Sci. USA. 1991;88:7552–7556. doi: 10.1073/pnas.88.17.7552
  7. Akaike A., Izumi Y. Overview. In: Nicotinic Acetylcholine Recept Signal Neuroprotection. Eds. Akaike A. Shimohama S., Misu Y. Singapore: Springer, 2018. doi: 10.1007/978-981-10-8488-1
  8. Willem M., Tahirovic S., Busche M.A., Ovsepian S.V., Chafai M., Kootar S., Hornburg D., Lewis D.B.E., Moore S., Daria A., et al. η-Secretase processing of APP inhibits neuronal activity in the hippocampus. Nature. 2015;526:443–447. doi: 10.1038/nature14864
  9. Du X., Wang X., Geng M. Alzheimer’s disease hypothesis and related therapies. Transl. Neurodegener. 2018;7. doi: 10.1186/s40035-018-0107-y
  10. Cummings J., Aisen P.S., Du Bois B., Frölich L., Jack C.R., Jones R.W., Morris J.C., Raskin J., Dowsett S.A., Scheltens P. Drug development in Alzheimer’s disease: the path to 2025. Alz. Res. Ther. 2016;8. doi: 10.1186/s13195-016-0207-9
  11. Gandy S., Sano M. Alzheimer disease: Solanezumab-prospects for meaningful interventions in AD? Nat. Rev. Neurol. 2015;11:669–670. doi: 10.1038/nrneurol.2015.218
  12. Karran E., De Strooper B. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nat. Rev. Drug Discov. 2022;21:306–318. doi: 10.1038/s41573-022-00391-w
  13. Lau H.H.C., Ingelsson M., Watts J.C. The existence of Aβ strains and their potential for driving phenotypic heterogeneity in Alzheimer’s disease. Acta. Neuropathol. 2021;142:17–39. doi: 10.1007/s00401-020-02201-2
  14. Alves G., Brønnick K., Aarsland D., Blennow K., Zetterberg H., Ballard C., Kurz M.W., Andreasson U., Tysnes O.B., Larsen J.P., et al. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson’s disease: the Norwegian ParkWest study. J. Neurol. Neurosurg. Psychiatry. 2010;81:1080–1086. doi: 10.1136/jnnp.2009.199950
  15. Matrone C., Iannuzzi F., Annunziato L. The Y682ENPTY687 motif of APP: Progress and insights toward a targeted therapy for Alzheimer’s disease patients. Ageing Res. Rev. 2019;52:120–128. doi: 10.1016/j.arr.2019.04.003
  16. Hudson G., Stutt A., Eccles M., Robinson L., Allcock L.M., Wesnes K.A., Chinnery P.F., Burn D.J. Genetic variation of CHRNA4 does not modulate attention in Parkinson’s disease. Neurosci. Lett. 2010;479:123–125. doi: 10.1016/j.neulet.2010.05.041
  17. Lim E.W., Aarsland D., Ffytche D., Taddei R.N., van Wamelen D.J., Wan Y.-M., Tan E.K., Ray Chaudhuri K. Amyloid-β and Parkinson’s disease. J. Neurol. 2019;266:2605–2619. doi: 10.1007/s00415-018-9100-8
  18. Kim Y.S., Joh T.H. Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson’s disease. Exp. Mol. Med. 2006;38:333–347. doi: 10.1038/emm.2006.40
  19. Shimohama S., Kawamata J. Roles of Nicotinic Acetylcholine Receptors in the Pathology and Treatment of Alzheimer’s and Parkinson’s Diseases. In: Nicotinic Acetylcholine Recept Signal Neuroprotection. Springer, 2018. P. 137–158. doi: 10.1007/978-981-10-8488-1_8
  20. Compta Y., Martí M.J., Ibarretxe-Bilbao N., Junqué C., Valldeoriola F., Muñoz E., Ezquerra M., Ríos J., Tolosa E. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson’s disease. Mov. Disord. 2009;24:2203–2210. doi: 10.1002/mds.22594
  21. Montine T.J., Shi M., Quinn J.F., Peskind E.R., Craft S., Ginghina C., Chung A.K., Kim H., Galasko D.R., Jankovic J., et al. CSF Aβ(42) and tau in Parkinson’s disease with cognitive impairment. Mov. Disord. 2010;25:2682–2685. doi: 10.1002/mds.2328
  22. Siderowf A., Xie S.X., Hurtig H., Weintraub D., Duda J., Chen-Plotkin A., Shaw M. L., Van Deerlin V., Trojanowski Q.J., Clark C., et al. CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease. Neurology. 2010;75:1055–1061. doi: 10.1212/WNL.0b013e3181f39a78
  23. Shi M., Bradner J., Hancock A.M., Chung K.A., Quinn J.F., Peskind E.R., Galasko D., Jankovic J., Zabetian C.P., Kim H.M., et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann. Neurol. 2011;69:570–580. doi: 10.1002/ana.22311
  24. Wang Y., Hancock A.M., Bradner J., Chung K.A., Quinn J.F., Peskind E.R., Galasko D., Jankovic J., Zabetian C.P., Kim H.M., et al. Complement 3 and factor h in human cerebrospinal fluid in Parkinson’s disease, Alzheimer’s disease, and multiple-system atrophy. Am. J. Pathol. 2011;178:1509–1516. doi: 10.1016/j.ajpath.2011.01.006
  25. Chu C.J., Yang Y.C., Wei J.X., Zhang L. Association of nicotinic acetylcholine receptor subunit alpha-4 polymorphisms with smoking behaviors in Chinese male smokers. Chin. Med. J. (Engl). 2011;124(11):1634–1638.
  26. Malnar M., Hecimovic S., Mattsson N., Zetterberg H. Bidirectional links between Alzheimer’s disease and Niemann-Pick type C disease. Neurobiol. Dis. 2014;72. doi: 10.1016/j.nbd.2014.05.03
  27. Martone R., Gonzales C., Ramaswamy G. Niemann-Pick Type C Disease: At the Nexus of Neurodegenerative and Neurodevelopmental Disorders. J. Park. Dis. Alzheimer. Dis. 2019;6(1). Article No. 10. doi: 10.13188/2376-922X.1000029
  28. Huang Y., Yu S., Wu Z., Tang B. Genetics of hereditary neurological disorders in children. Transl. Pediatr. 2014;3:108–119. doi: 10.3978/j.issn.2224-4336.2014.03.04
  29. Mattsson N., Olsson M., Gustavsson M.K., Kosicek M., Malnar M., Månsson J.-E., Blomqvist M., Gobom J., Andreasson U., Brinkmalm G., et al. Amyloid-β metabolism in Niemann-Pick C disease models and patients. Metab. Brain. Dis. 2012;27:573–85. doi: 10.1007/s11011-012-9332-8
  30. Shin S.D., Shin A., Mayagoitia K., Siebold L., Rubini M., Wilson C.G., Bellinger D.L., Soriano S. Loss of amyloid precursor protein exacerbates early inflammation in Niemann-Pick disease type C. J. Neuroinflammation. 2019;16. doi: 10.1186/s12974-019-1663-5
  31. Jin L.-W., Shie F.-S., Maezawa I., Vincent I., Bird T. Intracellular accumulation of amyloidogenic fragments of amyloid-beta precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities. Am. J. Pathol. 2004;164:975–985. doi: 10.1016/S0002-9440(10)63185-9
  32. Malnar M., Kosicek M., Mitterreiter S., Omerbasic D., Lichtenthaler S.F., Goate A., Hecimovic S. Niemann-Pick type C cells show cholesterol dependent decrease of APP expression at the cell surface and its increased processing through the beta-secretase pathway. Biochim. Biophys. Acta. 2010;1802:682–691. doi: 10.1016/j.bbadis.2010.05.006
  33. Stefulj J., Peric M., Malnar M., Kosicek M., Schweinzer C., Zivkovic J., Scholler M., Panzenboeck U., Hecimovic S. Pharmacological activation of LXRs decreases amyloid-β levels in Niemann-Pick type C model cells. Curr. Pharm. Biotechnol. 2013;14:582–593. doi: 10.2174/138920101131400224
  34. Mattsson N., Zetterberg H., Bianconi S., Yanjanin N.M., Fu R., Månsson J.-E., Porter F.D., Blennow K. Miglustat treatment may reduce cerebrospinal fluid levels of the axonal degeneration marker tau in niemann-pick type C. JIMD Rep. 2012;3:45–52. doi: 10.1007/8904_2011_47
  35. Stern S., Crisamore K., Schuck R., Pacanowski M. Evaluation of the landscape of pharmacodynamic biomarkers in Niemann-Pick Disease Type C (NPC). Orphanet J. Rare Dis. 2024;19. doi: 10.1186/s13023-024-03233-7
  36. Bryson J.B., Hobbs C., Parsons M.J., Bosch K.D., Pandraud A., Walsh F.S., Doherty P., Greensmith L. Amyloid precursor protein (APP) contributes to pathology in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Hum. Mol. Genet. 2012;21:3871–3882. doi: 10.1093/hmg/dds215
  37. Muresan V., Villegas C., Muresan Z.L. Functional interaction between amyloid-β precursor protein and peripherin neurofilaments: a shared pathway leading to Alzheimer’s disease and amyotrophic lateral sclerosis? Neurodegener. Dis. 2014;13:122–125. doi: 10.1159/000354238
  38. Matrone C. The paradigm of amyloid precursor protein in amyotrophic lateral sclerosis: The potential role of the 682YENPTY687 motif. Comput. Struct. Biotechnol. J. 2023;21:923–30. doi: 10.1016/j.csbj.2023.01.008
  39. Matrone C. A new molecular explanation for age-related neurodegeneration: the Tyr682 residue of amyloid precursor protein. Bioessays. 2013;35:847–852. doi: 10.1002/bies.201300041
  40. Pathak N., Vimal S.K., Tandon I., Agrawal L., Hongyi C., Bhattacharyya S. Neurodegenerative Disorders of Alzheimer, Parkinsonism, Amyotrophic Lateral Sclerosis and Multiple Sclerosis: An Early Diagnostic Approach for Precision Treatment. Metab. Brain Dis. 2022;37:67–104. doi: 10.1007/s11011-021-00800-w
  41. Sabatelli M., Lattante S., Conte A., Marangi G., Luigetti M., Del Grande A., Chiò A., Corbo M., Giannini F., Mandrioli J., et al. Replication of association of CHRNA4 rare variants with sporadic amyotrophic lateral sclerosis: the Italian multicentre study. Amyotroph. Lateral Scler. 2012;13:580–584. doi: 10.3109/17482968.2012.704926
  42. Sabatelli M., Eusebi F., Al-Chalabi A., Conte A., Madia F., Luigetti M., Mancuso I., Limatola C., Trettel F., Sobrero F., et al. Rare missense variants of neuronal nicotinic acetylcholine receptor altering receptor function are associated with sporadic amyotrophic lateral sclerosis. Hum. Mol. Genet. 2009;18:3997–4006. doi: 10.1093/hmg/ddp339
  43. Jalaiei A., Asadi M.R., Daneshmandpour Y., Rezazadeh M., Ghafouri-Fard S. Clinical, molecular, physiologic, and therapeutic feature of patients with CHRNA4 and CHRNB2 deficiency: A systematic review. J. Neurochem. 2024;169. doi: 10.1111/jnc.16200
  44. Couturier N., Hörner S.J., Nürnberg E., Joazeiro C., Hafner M., Rudolf R. Aberrant evoked calcium signaling and nAChR cluster morphology in a SOD1 D90A hiPSC-derived neuromuscular model. Front. Cell. Dev. Biol. 2024;12. doi: 10.3389/fcell.2024.1429759
  45. Moriconi C., Di Angelantonio S., Piccioni A., Trettel F., Sabatelli M., Grassi F. Mutant human β4 subunit identified in amyotrophic lateral sclerosis patients impairs nicotinic receptor function. Pflugers Arch. – Eur. J. Physiol. 2011;461:225–233. doi: 10.1007/s00424-010-0905-2
  46. Gentile A., Mori F., Bernardini S., Centonze D. Role of amyloid-β CSF levels in cognitive deficit in MS. Clin. Chim. Acta. 2015;449:23–30. doi: 10.1016/j.cca.2015.01.035
  47. Stampanoni Bassi M., Garofalo S., Marfia G.A., Gilio L., Simonelli I., Finardi A., Furlan R., Sancesario G.M., Di Giandomenico J., Storto M., et al. Amyloid-β Homeostasis Bridges Inflammation, Synaptic Plasticity Deficits and Cognitive Dysfunction in Multiple Sclerosis. Front. Mol. Neurosci. 2017;10. doi: 10.3389/fnmol.2017.00390
  48. Pietroboni A.M., Caprioli M., Carandini T., Scarioni M., Ghezzi L., Arighi A., Cioffi S., Cinnante C., Fenoglio C., Oldoni E., et al. CSF β-amyloid predicts prognosis in patients with multiple sclerosis. Mult. Scler. 2019;25:1223–1231. doi: 10.1177/1352458518791709
  49. Mizrachi T., Vaknin-Dembinsky A., Brenner T., Treinin M. Neuroinflammation Modulation via α7 Nicotinic Acetylcholine Receptor and Its Chaperone, RIC-3. Molecules. 2021;26. doi: 10.3390/molecules26206139
  50. Reale M., Di Bari M., Di Nicola M., D’Angelo C., De Angelis F., Velluto L., Tata A.M. Nicotinic receptor activation negatively modulates pro-inflammatory cytokine production in multiple sclerosis patients. Int. Immunopharmacol. 2015;29:152–157. doi: 10.1016/j.intimp.2015.06
  51. Gatta V., Mengod G., Reale M., Tata A.M. Possible Correlation between Cholinergic System Alterations and Neuro/Inflammation in Multiple Sclerosis. Biomedicines. 2020;8. doi: 10.3390/biomedicines8060153
  52. Di Bari M., Reale M., Di Nicola M., Orlando V., Galizia S., Porfilio I., Costantini E., D'Angelo C., Ruggieri S., Biagioni S., et al. Dysregulated Homeostasis of Acetylcholine Levels in Immune Cells of RR-Multiple Sclerosis Patients. Int. J. Mol. Sci. 2016;17. doi: 10.3390/ijms17122009
  53. Meyer P., Kurtz K., Thomae E., Becker G., Schildan A., Patt M., Lobsien D., Hesse S., Bergh F.T., Sabri O. Reduced cortical α4β2* nicotinic acetylcholine receptor binding and its relationship to impaired memory and attention in early stage multiple sclerosis: A 2-[18F]F-A-85380 (2FA) PET study. J. Nucl. Med. 2010;51:1792–1792. doi: 10.1016/j.neuroimage.2010.04.090
  54. Barykin E.P., Garifulina A.I., Tolstova A.P., Anashkina A.A., Adzhubei A.A., Mezentsev Y.V., Shelukhina I.V., Kozin S.A., Tsetlin V.I., Makarov A.A. Tetrapeptide Ac-HAEE-NH2 Protects α4β2 nAChR from Inhibition by Aβ. Int. J. Mol. Sci. 2020;21. doi: 10.3390/ijms21176272
  55. Kozin S.A., Barykin E.P., Mitkevich V.A., Makarov A.A. Anti-Amyloid Therapy of Alzheimer’s Disease: Current State And Prospects. Biochemistry (Moscow). 2018;83(9):1057–1067. doi: 10.1134/S0006297918090079
  56. Kozin S.A., Barykin E.P., Mitkevich V.A., Makarov A.A. Anti-amyloid Therapy of Alzheimer’s Disease: Current State and Prospects. Biochemistry (Moscow). 2018;83:1057–1067. doi: 10.1134/S0006297918090079
  57. Deigin V.I., Poluektova E.A., Beniashvili A.G., Kozin S.A., Poluektov Y.M. Development of Peptide Biopharmaceuticals in Russia. Pharmaceutics. 2022;14. doi: 10.3390/pharmaceutics14040716
  58. Kozin S.A., Makarov A.A. The Convergence of Alzheimer’s Disease Pathogenesis Concepts. Molecular Biology. 2019;53(6):896-903. doi: 10.1134/S0026893319060104
  59. Vilella A., Romoli B., Bodria M., Pons S., Maskos U., Zoli M. Evidence for a protective effect of the loss of α4-containing nicotinic acetylcholine receptors on Aβ-related neuropathology in Tg2576 mice. Front. Neurosci. 2023;17. doi: 10.3389/fnins.2023.1097857
  60. Lin Y.-F., Cheng C.-W., Shih C.-S., Hwang J.-K., Yu C.-S., Lu C.-H. MIB: Metal Ion-Binding Site Prediction and Docking Server. J. Chem. Inf. Model. 2016;56:2287–2291. doi: 10.1021/acs.jcim.6b00407
  61. Mazzaferro S., Kang G., Natarajan K., Hibbs R.E., Sine S.M. Structural bases for stoichiometry-selective calcium potentiation of a neuronal nicotinic receptor. Br. J. Pharmacol. 2024;181:1973–1992. doi: 10.1111/bph.16321
  62. Santoro A., Grimaldi M., Buonocore M., Stillitano I., D’Ursi A.M. Exploring the Early Stages of the Amyloid Aβ(1-42) Peptide Aggregation Process: An NMR Study. Pharm. (Basel). 2021;14(8). doi: 10.3390/ph14080732
  63. Van Zundert G.C.P., Rodrigues J.P.G.L.M., Trellet M., Schmitz C., Kastritis P.L., Karaca E., Melquiond A.S.J., van Dijk M., de Vries S.J., Bonvin A.M.J.J. The HADDOCK2.2 Web Server: User-Friendly Integrative Modeling of Biomolecular Complexes. J. Mol. Biol. 2016;428(4):720–725. doi: 10.1016/j.jmb.2015.09.014
  64. Tsvetkov P.O., Kulikova A.A., Golovin A.V., Tkachev Y.V., Archakov A.I., Kozin S.A., Makarov A.A. Minimal Zn2+ binding site of amyloid-β. Biophys. J. 2010;99. doi: 10.1016/j.bpj.2010.09.015
  65. Mitkevich V.A., Barykin E.P., Eremina S., Pani B., Katkova-Zhukotskaya O., Polshakov V.I., Adzhubei A.A., Kozin S.A., Mironov A.S., Makarov A.A., et al. Zn-dependent β-amyloid Aggregation and its Reversal by the Tetrapeptide HAEE. Aging and Dis. 2023;14(2):309–318. doi: 10.14336/AD.2022.0827
  66. Williams C.J., Headd J.J., Moriarty N.W., Prisant M.G., Videau L.L., Deis L.N., Verma V., Keedy D.A., Hintze B.J., Chen V.B., et al. MolProbity: More and better reference data for improved all-atom structure validation. Protein Sci. 2018;27:293–315. doi: 10.1002/pro.3330
  67. Valdés-Tresanco M.S., Valdés-Tresanco M.E., Valiente P.A., Moreno E. gmx_MMPBSA: A New Tool to Perform End-State Free Energy Calculations with GROMACS. J. Chem. Theory Comput. 2021;17(10):6281–6291. doi: 10.1021/acs.jctc.1c00645
  68. Miller B.R., McGee T.D., Swails J.M., Homeyer N., Gohlke H., Roitberg A.E. MMPBSA.py: An Efficient Program for End-State Free Energy Calculations. J. Chem. Theory Comput. 2012;8(9):3314–3321. doi: 10.1021/ct300418h
  69. Madeira F., Madhusoodanan N., Lee J., Eusebi A., Niewielska A., Tivey A.R.N., Lopez R., Butcher S. The EMBL-EBI Job Dispatcher Sequence Analysis Tools Framework in 2024. Nucleic Acids Res. 2024;52:W521–W525. doi: 10.1093/nar/gkae241
  70. Arapidi G.P., Urban A.S., Osetrova M.S., Shender V.O., Butenko I.O., Bukato O.N., Kuznetsov A.A., Saveleva T.M., Nos G.A., Ivanova O.M., et al. Non-human peptides revealed in blood reflect the composition of intestinal microbiota. BMC Biol. 2024;22(1). doi: 10.1186/s12915-024-01975-1
  71. Baig M.H., Ahmad K., Saeed M., Alharbi A.M., Barreto G.E., Ashraf G.M., Choi I. Peptide based therapeutics and their use for the treatment of neurodegenerative and other diseases. Biomed. Pharmacother. 2018;103:574–581. doi: 10.1016/j.biopha.2018.04.025
  72. Ding Q., Tanigawa K., Kaneko J., Totsuka M., Katakura Y., Imabayashi E., Matsuda H., Hisatsune T. Anserine/Carnosine Supplementation Preserves Blood Flow in the Prefrontal Brain of Elderly People Carrying APOE e4. Aging. Dis. 2018;9:334–345. doi: 10.14336/AD.2017.0809
  73. Hipkiss A.R. Aging risk factors and Parkinson’s disease: contrasting roles of common dietary constituents. Neurobiol. Aging. 2014;35(6):1469–1472. doi: 10.1016/j.neurobiolaging.2013.11.032
  74. Boldyrev A.A., Aldini G., Derave W. Physiology and pathophysiology of carnosine. Physiol. Rev. 2013;93(4):1803–1845. doi: 10.1152/physrev.00039.2012
  75. Hipkiss A.R. On the Relationship between Energy Metabolism, Proteostasis, Aging and Parkinson’s Disease: Possible Causative Role of Methylglyoxal and Alleviative Potential of Carnosine. Aging. Dis. 2017;8:334–345. doi: 10.14336/AD.2016.1030
  76. Bellia F., Vecchio G., Rizzarelli E. Carnosinases, their substrates and diseases. Molecules. 2014;19:2299–2329. doi: 10.3390/molecules19022299
  77. Blennow K., Hampel H., Weiner M., Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 2010;6:131–144. doi: 10.1038/nrneurol.2010.4
  78. Perrin R.J., Craig-Schapiro R., Malone J.P., Shah A.R., Gilmore P., Davis A.E., Roe C.M., Peskind E.R., Li G., Galasko D.R., et al. Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer’s Disease. PLoS ONE. 2011;6. doi: 10.1371/journal.pone.0016032
  79. Kaneko J., Enya A., Enomoto K., Ding Q., Hisatsune T. Anserine (beta-alanyl-3-methyl-L-histidine) improves neurovascular-unit dysfunction and spatial memory in aged AβPPswe/PSEN1dE9 Alzheimer’s-model mice. Sci. Rep. 2017;7. doi: 10.1038/s41598-017-12785-7
  80. Masuoka N., Yoshimine C., Hori M., Tanaka M., Asada T., Abe K., Hisatsune T. Effects of Anserine/Carnosine Supplementation on Mild Cognitive Impairment with APOE4. Nutrients. 2019;11. doi: 10.3390/nu11071626
  81. Wu G. Important roles of dietary taurine, creatine, carnosine, anserine and 4-hydroxyproline in human nutrition and health. Amino Acids. 2020;52:329–360. doi: 10.1007/s00726-020-02823-6
  82. Morais L.H., Boktor J.C., MahmoudianDehkordi S., Kaddurah-Daouk R., Mazmanian S.K. α-synuclein overexpression and the microbiome shape the gut and brain metabolome in mice. Npj. Park. Dis. 2024;10:1–12. doi: 10.1038/s41531-024-00816-w
  83. Kim K. Glutathione in the Nervous System as a Potential Therapeutic Target to Control the Development and Progression of Amyotrophic Lateral Sclerosis. Antioxidants (Basel). 2021;10(7). doi: 10.3390/antiox10071011
  84. Weiduschat N., Mao X., Hupf J., Armstrong N., Kang G., Lange D.J., Mitsumoto H., Shungu D.C. Motor cortex glutathione deficit in ALS measured in vivo with the J-editing technique. Neurosci. Lett. 2014;570:102–107. doi: 10.1016/j.neulet.2014.04.020
  85. Carvalho A.N., Lim J.L., Nijland P.G., Witte M.E., Van Horssen J. Glutathione in multiple sclerosis: more than just an antioxidant? Mult. Scler. 2014;20:1425–1431. doi: 10.1177/1352458514533400
  86. Ferreira B., Mendes F., Osorio N., Caseiro A., Gabriel A., Valado A. Glutathione in multiple sclerosis. Br. J. Biomed. Sci. 2013;70:75–79. doi: 10.1080/09674845.2013.11669939
  87. Hanas J.S., Hocker J.R.S., Vannarath C.A., Lerner M.R., Blair S.G., Lightfoot S.A., Hanas R.J., Couch J.R., Hershey L.A. Distinguishing Alzheimer’s Disease Patients and Biochemical Phenotype Analysis Using a Novel Serum Profiling Platform: Potential Involvement of the VWF/ADAMTS13 Axis. Brain Sci. 2021;11. doi: 10.3390/brainsci11050583
  88. Kumar V., Patiyal S., Dhall A., Sharma N., Raghava G.P.S. B3Pred: A Random-Forest-Based Method for Predicting and Designing Blood–Brain Barrier Penetrating Peptides. Pharmaceutics. 2021;13. doi: 10.3390/pharmaceutics13081237
  89. Banks W.A. Peptides and the blood–brain barrier. Peptides. 2015;72:16–19. doi: 10.1016/j.peptides.2015.03.010
  90. Kopylov A.T., Karpova E.M. Diagnostic test system for determining biomarker specific for neurodegenerative diseases or neurodegenerative disorders: patent No. RU2827060C1. Moscow: Rospatent, 2024. URL: https://new.fips.ru/iiss/document.xhtml?faces-redirect=true&id=8b6d80bd44f813b11046466ec117976a (accessed 22.07.2025).
  91. Kozin S.A., Kopylov A.T., Karpova E.M., Yakovlev R.Y. Physiologically active substance SRFM as blood biomarker for diagnosing human neurodegenerative disorders and diseases: patent No. RU2822604C1. Moscow: Rospatent, 2024. URL: https://new.fips.ru/iiss/document.xhtml?faces-redirect=true&id=ee32981ac4a9edc0ff0cce378738f5c6 (accessed: 22.07.2025).
  92. Yamada S., Arikawa S. An ectotherm homologue of human predicted gene NAT16 encodes histidine N-acetyltransferase responsible for Nα-acetylhistidine synthesis. Biochim. Biophys. Acta. 2014;1840:434–442. doi: 10.1016/j.bbagen.2013.10.004
  93. Shaku M.T., Ocius K.L., Apostolos A.J., Pires M.M., Van Nieuwenhze M.S., Dhar N., Kana B.D. Amidation of glutamate residues in mycobacterial peptidoglycan is essential for cell wall cross-linking. Front. Cell. Infect. Microbiol. 2023;13. doi: 10.3389/fcimb.2023.1205829
Содержание
Оригинальная статья
Никольский К.С., Куликова Л.И., Руднев В.Р., Петровский Д.В., Габестро И.С., Каем С.Л., Карпова Е.М., Копылов А.Т., Кайшева А.Л. Исследование интерфейса связывания бета-амилоида с кандидатным маркером нейродегенеративных заболеваний. Математическая биология и биоинформатика. 2025;20(1):212-235. doi: 10.17537/2025.20.212
(опубликована на рус. яз.)

Аннотация (рус.)
Аннотация (англ.)
Полный текст (рус., pdf)
Список литературы

 
  Copyright ИМПБ РАН © 2005-2026